|
|
|
|
Hepatitis B virus mutations may help predict liver cancer risk
Washington, July 3 : Scientists from Second Military Medical University in Shanghai have revealed that mutations in the DNA of hepatitis B virus (HBV) might help predict which patients are at increased risk of developing liver cancer,...
|
|
|
Hepatitis B virus mutations may help predict liver cancer risk
PM IST Scientists from Second Military Medical University in Shanghai have revealed that mutations in the DNA of hepatitis B virus (HBV) might help predict which patients are at increased risk of developing liver cancer,HBV infection...
|
|
|
JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
Certain mutations in the DNA of the hepatitis B virus (HBV) are associated with the development of liver cancer and may help predict which patients with HBV infections are at increased risk of the disease, according to a large meta...
|
|
|
Hepatitis B Virus Mutations May Predict Risk Of Liver Cancer
Certain mutations in the DNA of the hepatitis B virus (HBV) are associated with the development of liver cancer and may help predict which patients with HBV infections are at increased risk of the disease, according to a large meta...
|
|
|
Hepatitis B Virus Mutations May Predict Risk Of Liver Cancer
Certain mutations in the DNA of the hepatitis B virus (HBV) are associated with the development of liver cancer and may help predict which patients with HBV infections are at increased risk of the disease, according to a large meta...
|
|
|
Time-Released Interferon Locteron Study Enrollment Completed
- EASL: Randomized Trial Comparing Systemic and Local Reactions to Controlled-release Interferon Alpha2b and Pegylated-interferon Alpha2b in Hepatitis C Patients Who Failed Prior Treatment - (05/07/09) Co Press Release: Biolex presents...
National AIDS Treatment Advocacy Project:
Jul 4 2009 11:45AM
Matching: hepatitis chronic
|
Find similar documents
|
|
|
|
Hepatitis B Virus - Scientists at University of Tokyo target hepatitis B virus
Learn more about a six-week, no-risk free trial of Hepatitis Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Hepatitis B Virus According to recent research...
|
|
|
Hepatitis B Virus - Studies from K. Szymanska et al have provided new data on hepatitis B virus
Learn more about a six-week, no-risk free trial of Hepatitis Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Hepatitis B Virus Studies from K. Szymanska...
|
|
|
Promising Prospect for Chinese Hepatitis B Vaccine Market Driven by the Policies
www.shcri.com -- In 2009, 23.3 million populations will need vaccinating, accounting for 31% of the populations that should be vaccinated.China is the area of high incidence of hepatitis B and the hepatitis B virus carriers...
|
|
|
Hepatitis B virus mutations may help predict liver cancer risk
_ Hepatitis B virus mutations may help predict liver cancer risk.
|
|
|
Promising Prospect for Chinese Hepatitis B Vaccine Market Driven by the Policies
_ Promising Prospect for Chinese Hepatitis B Vaccine Market Driven by the Policies.
|
|
|
Hepatocellular Cancer - New findings reported from H.H. Lee and co-authors describe advances in hepatocellular
Learn more about a six-week, no-risk free trial of Hepatitis Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Hepatocellular Cancer New findings reported from H.H. Lee...
|
|
|
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preli
Print Save in My Library Free Full Text Fluge O et al.- B-lymphocytes are involved in CFS pathogenesis for a subset of patients. Benefit for all CFS symptoms, the delayed symptom relief following B-cell depletion, the...
|
|
|
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrom
_ Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrom.
|
|
|
JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
Certain mutations in the DNA of the hepatitis B virus (HBV) are associated with the development of liver cancer and may help predict which patients with HBV infections are at increased risk of the disease, according to a large meta...
|
|
|
JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
_ JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer.
|
|
|
Hepatitis C Virus Therapy: Researchers at Derriford Hospital release new data on hepatitis C virus therapy
Researchers at Derriford Hospital release new data on hepatitis C virus therapy Fresh data on hepatitis C virus are presented in the report 'The impact of hepatic steatosis on the natural history of chronic hepatitis C infection.' ...
|
|
|
Academy Sends Congress a Solution to Fix Broken Physician Payment System
Newswise The American Academy of Neurology Professional Association has sent a letter to Congress offering a solution to fix the way physicians are reimbursed under Medicare for treating patients with severe or disabling chronic...
|
|
|
ASIA impairment scale conversion in traumatic SCI: is it related with the ability to walk? A descriptive compa
J J van Middendorp1, A J F Hosman1, M H Pouw1, EM-SCI Study Group and H Van de Meent2 1Spine Unit, Department of Orthopaedics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands 2Department of Rehabilitation Medicine,...
|
|
|
Amarillo, CytoPharm Intiates Enrollment For Hepatitis-C Study
Aim of trial is to reduce virologic relapse rate for patients who have completed the standard combination therapy Amarillo (ABI) and CytoPharm have started the enrollment for a study of ABI's oral interferon-alpha lozenges, for chronic...
|
|
|
2. Personalized Anti-Cancer Vaccine, BiovaxID[R], Targeting B-cell Lymphomas
Biovest and idis Partner to Facilitate Patient Access to Lymphoma Vaccine Phase III Study Results to Be Presented at 'Best of ASCO' in Paris TAMPA, Fla.-- Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of...
|
|
|
Hyperion Therapeutics Raises $60 Million Series C
SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and...
|
|
|
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomela
Agomelatine is a novel antidepressant acting as a melatonergic receptor agonist and serotonergic (5-HT2C) receptor antagonist.In adult rats, chronic agomelatine treatment enhanced cell proliferation and neurogenesis in the ventral...
|
|
|
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomela
Agomelatine is a novel antidepressant acting as a melatonergic receptor agonist and serotonergic (5-HT2C) receptor antagonist.In adult rats, chronic agomelatine treatment enhanced cell proliferation and neurogenesis in the ventral...
|
|
|
BiovaxID Now Available In Europe
BiovaxID, a therapeutic anti-cancer vaccine produced by Biovest, a subsidiary of Accentia Biopharmaceuticals, is now available in Europe.BiovaxID is a personalised vaccine, which uses the patient's own immune system to treat follicular...
|
